Eledon Pharmaceuticals, Inc.
ELDN · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | – | – | – |
| R&D Expenses | $52 | $30 | $27 | $24 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $18 | $12 | $12 | $13 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $70 | $43 | $39 | $37 |
| Operating Income | -$71 | -$43 | -$40 | -$37 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $35 | -$74 | -$48 | $0 |
| Pre-Tax Income | -$36 | -$117 | -$88 | -$37 |
| Tax Expense | $0 | $0 | $0 | -$2 |
| Net Income | -$36 | -$117 | -$88 | -$35 |
| % Margin | – | – | – | – |
| EPS | -0.75 | -0.002 | -6.13 | -2.33 |
| % Growth | -46,775% | 100% | -163.1% | – |
| EPS Diluted | -0.75 | -1.64 | -6.13 | -2.33 |
| Weighted Avg Shares Out | 49 | 25 | 14 | 15 |
| Weighted Avg Shares Out Dil | 49 | 25 | 14 | 15 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$35 | -$116 | -$88 | -$37 |
| % Margin | – | – | – | – |